Peking University Cancer Hospital & Institute

This study tests whether a higher dose (160 mg) of the targeted drug firmonertinib can shrink or control advanced EGFR-mutant lung cancer in people whose tumors stayed stable after 8 weeks on the standard 80 mg dose. About 28 adults with stage IV non-small cell lung cancer and no…

This study tests whether adding the immunotherapy drug adebrelimab to standard chemoradiotherapy can help control limited-stage small-cell lung cancer. About 30 adults aged 18-75 will receive the combination, then continue adebrelimab alone. The goal is to see if the treatment de…

This study tests whether giving a high dose of firmonertinib (a targeted pill) plus bevacizumab (an IV drug that blocks blood vessel growth) before surgery can shrink tumors in people with a specific type of lung cancer (EGFR-mutated, stage II-IIIB). About 62 adults whose cancer …

This study compares a new drug called SHR-A1811 with a standard combination therapy (pyrotinib plus capecitabine) in 100 people whose HER2-positive advanced breast cancer stopped responding to trastuzumab. The goal is to see which treatment works better at delaying cancer growth.…

This study tests whether using a patient's own gut bacteria (autologous probiotics) can reduce severe bowel problems after temporary ileostomy reversal in rectal cancer survivors. About 40 adults who had rectal cancer surgery with a temporary ileostomy will receive their own cult…

This study tests a drug called ivonescimab, given alone or with chemotherapy, before and after surgery for people with a certain type of lung cancer (non-small cell lung cancer) that can be removed. The goal is to see if using less chemotherapy based on a patient's PD-L1 level ca…

This study tests whether a combination of two drugs (vorolanib and everolimus) works better than the standard drug sunitinib for people with advanced kidney cancer that has gotten worse after immunotherapy. About 116 adults will be randomly assigned to one of the two treatments. …

This study looks at whether adding pyrotinib to two standard drugs (trastuzumab and pertuzumab) can help keep HER2-positive advanced breast cancer from growing longer. About 42 adults with advanced or recurrent HER2-positive breast cancer will receive this combination as maintena…

This study tests whether adding a new drug (recaticimab) to standard immunotherapy and chemotherapy before surgery can improve outcomes for people with resectable non-small cell lung cancer. About 78 adults with stage II to IIIB lung cancer will receive the combination treatment …

This study looks at people with limited-stage small cell lung cancer whose disease is under control after standard chemotherapy and radiation. A special blood test (MRD) checks for tiny bits of cancer DNA left behind. If the test is positive, patients get a combination of immunot…

This study tests a standardized treatment plan for esophageal fistula, a severe complication of advanced esophageal cancer that can cause life-threatening infections and malnutrition. The plan includes sealing the fistula with stents, targeted antibiotics, nutritional support, an…

This study tests an experimental drug called SHR-A1811 in 51 women with HER2-positive breast cancer that has spread to the brain. Some participants also have cancer in the lining of the brain and spinal cord. The goal is to see if the drug is safe and can shrink or control these …

This study tests whether a short course of radiation that spares the lymph nodes, followed by an immunotherapy drug (PD-1 inhibitor), can completely eliminate rectal cancer before surgery. It includes 44 adults with stage II-III rectal cancer. The goal is to see if this approach …

This study tests whether adding the drug adebrelimab (an immunotherapy) after standard chemoradiotherapy can help control limited-stage small cell lung cancer for longer. About 76 adults aged 18-75 with untreated, localized disease will be enrolled. The main goal is to see if thi…

This study tests whether adding radiation and two immunotherapy drugs to standard chemotherapy and targeted therapy can help control a specific type of advanced rectal cancer (RAS-mutant/MSS). About 106 adults with metastatic rectal cancer will be randomly assigned to receive eit…

This study will compare two types of PET/MRI scans to see which one is better at finding cancer that has spread to lymph nodes in people with middle to high rectal cancer. About 30 patients who have not yet been treated will get both scans before surgery. The goal is to see if th…

This study tests a special PET scan that uses a radioactive probe to detect PD-L1, a protein on tumor cells. It aims to help doctors identify which patients with lung cancer, melanoma, or other solid tumors are most likely to benefit from immunotherapy. About 40 adults will recei…

This study tests whether a traditional Chinese medicine hand and foot bath can reduce nerve pain and numbness caused by chemotherapy in breast cancer patients. About 78 adults with nerve symptoms will either receive the herbal bath or a standard vitamin treatment. The goal is to …

This study tests a robotic system that helps doctors mark small lung nodules with a dye before surgery. The goal is to make it easier for surgeons to find and remove these nodules during a minimally invasive procedure. About 50 adults with hard-to-locate lung nodules will take pa…

This study explores whether special PET scans can help doctors tailor chemotherapy for early-stage HER2-positive breast cancer. About 156 participants will have their treatment adjusted based on how their tumor responds after two cycles, either intensifying or reducing therapy. T…

This study will follow 255 people with esophageal cancer to see how the disease changes over time. Researchers will use multiple tests, including genetic analysis of tumors and blood, imaging, and immune system markers. The goal is to better predict which patients are at risk for…